[ad_1]
International Flavors & Fragrances (IFF) is starting to give investors a more credible recovery case than it had a year ago. In the first quarter of 2026, reported sales were $2.74 billion, down 4% year over year, but comparable currency-neutral sales increased 3%. Adjusted operating EBITDA was $568 million, down 2% on a reported basis but up 8% on a comparable currency-neutral basis, with margin reaching 20.7%, the highest level since the second quarter of 2022, according to the company’s release.
That split is the key to the stock. The reported numbers still look messy because IFF is moving through portfolio changes, including the divestiture of its Soy Crush, Concentrates, and Lecithin business. But beneath that noise, the operating trend looks better than the headline revenue line suggests. For a stock often framed as a discounted-value situation, the real question is whether improving volume, productivity, and mix can turn a restructuring story into a steadier earnings-and-cash-flow recovery.
What the latest reported period says about sales, margins, and segment mix
The first-quarter release showed broad-based underlying demand across the core portfolio. Taste generated $656 million of reported sales and 2% comparable currency-neutral sales growth, while adjusted operating EBITDA rose 18% on a comparable currency-neutral basis. Health & Biosciences reported $595 million of sales with 5% comparable currency-neutral growth and 7% comparable currency-neutral adjusted operating EBITDA growth. Scent posted $651 million of sales with 1% comparable currency-neutral growth, and Food Ingredients delivered $839 million of sales with 3% comparable currency-neutral growth and 12% comparable currency-neutral adjusted operating EBITDA growth.
That matters because the recovery is not being driven by just one pocket of the business. Taste, Health & Biosciences, Scent, and Food Ingredients all posted positive comparable currency-neutral sales growth in the quarter. The one softer area inside Scent was Fragrance Ingredients, but even there volume growth and productivity gains offset part of the price-to-input-cost pressure.
The annual backdrop also looks healthier than the market sometimes gives it credit for. In 2025, IFF generated $10.89 billion of net sales, down from $11.48 billion in 2024, but cost of sales fell to $6.95 billion from $7.36 billion and gross margin improved as lower costs and productivity gains offset some of the portfolio disruption. Selling and administrative expense also declined to $1.83 billion from $2.00 billion, while interest expense fell to $229 million from $305 million because of lower debt outstanding.
Where the turnaround or recovery case actually stands
The main reason the recovery case is getting more credible is that underlying growth is no longer isolated. Management reaffirmed full-year 2026 sales guidance of $10.5 billion to $10.8 billion and adjusted operating EBITDA guidance of $2.05 billion to $2.15 billion, even after updating the outlook to reflect the Soy Crush divestiture closing on March 2, 2026 rather than April 1, 2026. That suggests the company believes the core portfolio can absorb portfolio pruning without losing the broader operating trajectory.
IFF also has a more coherent segment structure than the headline valuation debate sometimes implies. In 2025, Taste adjusted operating EBITDA reached $478 million, Health & Biosciences reached $594 million, Scent reached $515 million, and Food Ingredients reached $423 million. Those businesses each contributed meaningful earnings power even before any re-rating from cleaner execution. The problem area was Pharma Solutions, where sales fell sharply on a reported basis because of divestitures, making headline comparisons look worse than the underlying continuing portfolio.
In plain English, the stock does not need a heroic macro rebound to work. It needs the cleaner core portfolio to keep producing volume growth and margin expansion while divestiture noise fades.
How debt, cash generation, and portfolio exposure shape the valuation debate
Balance-sheet repair is one reason investors still treat IFF as a discounted name. At December 31, 2025, total debt was $6.03 billion, cash and cash equivalents were $590 million, and net debt was $5.44 billion. Even so, the company said its net debt-to-credit-adjusted-EBITDA ratio was 2.59x at year-end, well below the 3.75x covenant threshold that applied after September 30, 2025.
That gives IFF more room than it had earlier in the post-DuPont integration period, but it does not make the balance sheet irrelevant. A company with more than $5 billion of net debt still needs operating consistency. The good news is that management describes operating cash flow as the primary source of funds for capital spending, dividends, share repurchases, and debt service, and says existing cash flow, planned divestiture proceeds, and credit-facility capacity should be sufficient for investing and financing needs.
The portfolio mix cuts both ways in the valuation debate. IFF gets diversification benefits from a global footprint, with about 72% of 2025 net sales generated outside the U.S. But that also means investors must tolerate more currency noise, region-by-region demand swings, and raw-material volatility than they would in a simpler domestic staples story.
What investors should watch next
The best near-term signal is whether comparable currency-neutral growth stays positive across the core businesses after the portfolio moves annualize. If that happens while adjusted operating EBITDA keeps rising on the same basis, the stock has a better chance of being viewed as a recovery compounder instead of a permanently discounted restructuring story.
The risk is that the cleaner first-quarter pattern proves temporary. Scent still has pressure in Fragrance Ingredients, reported sales are still declining year over year, and IFF remains exposed to the kind of input-cost and currency swings that can interrupt margin recovery. For the opportunity case to hold, the company has to keep converting productivity and volume gains into steadier cash generation and lower leverage.
Key Signals for Investors
- IFF’s first-quarter reported sales fell 4%, but comparable currency-neutral sales rose 3%, which suggests the underlying business is improving faster than the headline revenue line indicates.
- All four core segments posted positive comparable currency-neutral sales growth, giving the recovery story broader support than a one-segment rebound would provide.
- Year-end 2025 net debt of $5.44 billion is still sizable, so the valuation case depends on sustained EBITDA improvement and continued balance-sheet discipline.
- Full-year 2026 guidance of $10.5 billion to $10.8 billion of sales and $2.05 billion to $2.15 billion of adjusted operating EBITDA leaves room for upside only if the post-divestiture core portfolio keeps executing.
Sources
- IFF Reports First Quarter 2026 Results. URL: https://ir.iff.com/news-releases/news-release-details/iff-reports-first-quarter-2026-results
- International Flavors & Fragrances Inc. Form 10-K for the year ended December 31, 2025. URL: https://www.sec.gov/Archives/edgar/data/51253/000005125326000006/iff-20251231.htm
[ad_2]
Source link